About Us

Pioneering the science of
the Metabolome.

Human Metabolome Technologies America is the US operations of HMT — a Japan-based biotechnology company founded in 2003 that developed the core CE-MS metabolomics technology underpinning everything we offer. We bring 23 years of analytical innovation, scientific partnership, and metabolomics expertise to researchers across pharma, biotech, food science, and clinical research.

Get in Touch Our Platforms →

Human Metabolome Technologies (HMT) was founded in July 2003 by Professor Masaru Tomita, Ph.D., Director of the Institute for Advanced Biosciences (IAB) at Keio University, and Professor Tomoyoshi Soga, Ph.D., who established the cutting-edge CE-MS based metabolomics technology that forms HMT's core capability. Prof. Soga's work gave the world a practical method for resolving and quantifying the polar metabolome with a precision and depth that LC-MS cannot match.

HMT can identify more than 1,000 species of metabolites using CE-MS based metabolome analysis. The company has developed an original software analysis platform alongside its measurement technologies — CE-MS, LC-MS, and MS/MS — and continues to advance the field in collaboration with IAB at Keio University.

"HMT's primary aim is to provide complete solutions for metabolome analysis in drug design, diagnostic technology, and food production — serving human and animal sample types as a full-service metabolomics partner."

HMT has established partnerships with Mizkan Group Corporation, Ajinomoto Co. Inc., and Mitsubishi Pharma Corporation, and has received government funding from Japan's New Energy and Industrial Technology Development Organization (NEDO). In 2025, HMT transitioned to the Tokyo Stock Exchange Standard Market — reflecting its position as a recognised leader in metabolomics technology.

HMT America, based in Boston MA, brings the full HMT platform suite to North American and international researchers — with the same scientific collaboration and free interpretation that have defined HMT's reputation for over two decades.

2003
Founded at Keio University IAB, Japan
>1,000
Publications Using HMT Technology
>1,000
Metabolites Detectable Per Sample
23+
Years of CE-MS Leadership
History
Over two decades of metabolomics innovation
2003
HMT founded at Keio University's Institute for Advanced Biosciences by Prof. Masaru Tomita and Prof. Tomoyoshi Soga. CE-MS based metabolomics platform established.
2007
NEDO government funding awarded. Strategic partnerships established with Mizkan Group, Ajinomoto Co., and Mitsubishi Pharma Corporation.
2012
OMEGA Scan platform commercialised — delivering >1,000 polar metabolite detections per sample. Virtual Human Database development begins.
2016
HMT America established in Boston, MA — bringing CE-MS metabolomics services to North American pharmaceutical, biotech, and academic researchers.
2019
UCSF collaboration for MDD biomarker validation. Expansion of platform portfolio to include F-SCOPE, D/L Amino Acids, and Peptidomics.
2025
HMT transitions to Tokyo Stock Exchange Standard Market. Sugar Panel launched. Continued expansion of targeted metabolomics platform suite.
HMT America Team

The scientists behind your study

Our Boston-based team works directly with every client — from study design through data interpretation. Photos and bios below reflect the team as of 2025; contact us for the most current team information.

Alexander Buko
Alexander Buko, Ph.D.
Vice President, Business and Product Development
Dr. Buko brings over 40 years of pharmaceutical experience with the FDA, Abbott Labs, and Biogen Idec, where he held the position of Senior Director of Translational Medicine. Alex has successfully led large-scale omics projects in neurology, immunology, and oncology. With extensive experience in protein and metabolite-based profiling, Alex leads project management and development of HMT's biomarker-based platforms.
Gina Johnson
Gina Johnson, MSc.
Scientific Project Coordinator
Gina Johnson is a biologist with a strong background in ecology, evolution, and animal behavior. Her thesis work focused on the animal microbiome and how specific groups of microbes may influence life history traits and phenotypes. Gina brings skills in bioinformatic and statistical analysis, along with three years of teaching experience, and aids clients in data analysis and exploration.
Parinda Tennakoon
Parinda Tennakoon, Ph.D.
Senior Scientific Project Coordinator
Parinda (Pari) is a seasoned scientist specializing in oncology R&D, metabolomics, and stem cell research. His prior work includes investigating therapy resistance in breast cancer and developing stem cell therapies for lung diseases. Driven by a profound passion for translational research, Pari supports researchers in project development and data analysis.